IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice
- PMID: 22131335
- DOI: 10.4049/jimmunol.1102224
IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice
Abstract
Psoriasis is a common chronic autoimmune skin disease of unknown cause that involves dysregulated interplay between immune cells and keratinocytes. IL-22 is a cytokine produced by the TH1, TH17, and TH22 subsets that are functionally implicated in the psoriatic pathology. We assessed the role of IL-22 in a mouse model where psoriasiform skin inflammation is triggered by topical application of the TLR7/8 agonist imiquimod. At the macroscopic level, scaly skin lesions induced by daily applications of imiquimod in wild-type mice were almost totally absent in IL-22-deficient mice or in mice treated with a blocking anti-IL-22 Ab. At the microscopic level, IL-22-deficient mice showed a dramatic decrease in the development of pustules and a partial decrease in acanthosis. At the molecular level, the absence or inhibition of IL-22 strongly decreased the expression of chemotactic factors such as CCL3 and CXCL3 and of biomarkers such as S100A8, S100A7, and keratin 14, which reflect the antimicrobial and hyperproliferative responses of keratinocytes. IL-22 also played a major role in neutrophil infiltration after imiquimod treatment. IL-23 was required for IL-22 production, and γδ TCR lymphocytes represented the major source of IL-22 in lymph nodes from imiquimod-treated mice. However, T cells were not absolutely required for IL-22 production because imiquimod-induced IL-22 expression in the skin is still preserved in Rag2(-/-) mice. Taken together, our data show that IL-22 is required for psoriasis-like lesions in the mouse imiquimod model and is produced by both T cells and innate immune cells.
Similar articles
-
Cellular sources of IL-17 in psoriasis: a paradigm shift?Exp Dermatol. 2014 Nov;23(11):799-803. doi: 10.1111/exd.12487. Exp Dermatol. 2014. PMID: 25039885 Review.
-
IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells.J Invest Dermatol. 2014 Jul;134(7):1912-1921. doi: 10.1038/jid.2014.98. Epub 2014 Feb 25. J Invest Dermatol. 2014. PMID: 24569709
-
An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling.J Invest Dermatol. 2013 Feb;133(2):441-51. doi: 10.1038/jid.2012.318. Epub 2012 Sep 6. J Invest Dermatol. 2013. PMID: 22951726
-
Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice.J Clin Invest. 2012 Jun;122(6):2252-6. doi: 10.1172/JCI61862. Epub 2012 May 1. J Clin Invest. 2012. PMID: 22546855 Free PMC article.
-
Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop.Exp Dermatol. 2000 Feb;9(1):1-10. doi: 10.1034/j.1600-0625.2000.009001001.x. Exp Dermatol. 2000. PMID: 10688368 Review.
Cited by
-
Review: A Contemporary, Multifaced Insight into Psoriasis Pathogenesis.J Pers Med. 2024 May 16;14(5):535. doi: 10.3390/jpm14050535. J Pers Med. 2024. PMID: 38793117 Free PMC article. Review.
-
Association of Interleukin 23 Receptor Polymorphisms with Predisposition to Rheumatoid Arthritis: An Updated Meta and Trial Sequential Analysis.Biochem Genet. 2024 Jan 25. doi: 10.1007/s10528-023-10644-x. Online ahead of print. Biochem Genet. 2024. PMID: 38270697
-
Application of Luteolin in Neoplasms and Nonneoplastic Diseases.Int J Mol Sci. 2023 Nov 6;24(21):15995. doi: 10.3390/ijms242115995. Int J Mol Sci. 2023. PMID: 37958980 Free PMC article. Review.
-
Cellular Mechanisms of Psoriasis Pathogenesis: A Systemic Review.Clin Cosmet Investig Dermatol. 2023 Sep 14;16:2503-2515. doi: 10.2147/CCID.S420850. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 37727872 Free PMC article. Review.
-
Improved Production of Anti-FGF-2 Nanobody Using Pichia pastoris and Its Effect on Antiproliferation of Keratinocytes and Alleviation of Psoriasis.Arch Immunol Ther Exp (Warsz). 2023 Aug 26;71(1):20. doi: 10.1007/s00005-023-00685-w. Arch Immunol Ther Exp (Warsz). 2023. PMID: 37632545
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials